Infliximab and Tofacitinib Attenuate Neutralizing Antibody Responses Against SARS-CoV-2 Ancestral and Omicron Variants in Inflammatory Bowel Disease Patients Following 3 Doses of COVID-19 Vaccine

Thumbnail
URI
https://rde.dspace-express.com/handle/11287/622735
Author
Liu, Z.
Alexander, J. L.
Lin, K. W.
Ahmad, T.
Pollock, K. M.
Powell, N.
Date
2022-10-19
Journal
Gastroenterology
Type
Journal Article
Publisher
Elsevier
DOI
10.1053/j.gastro.2022.10.010
Rights
© 2022 by the AGA Institute.
Metadata
Show full item record
Citation
Gastroenterology. 2022 Oct 19:S0016-5085(22)01184-2. doi: 10.1053/j.gastro.2022.10.010.
Publisher URL
https://linkinghub.elsevier.com/retrieve/pii/S0016-5085(22)01184-2
Note
The article is available via Open Access. Click on the 'Additional link' above to access the full-text.
Collections
© 2022 by the AGA Institute.
Except where otherwise noted, this item's license is described as © 2022 by the AGA Institute.